Submit to Marine Drugs Review for Marine Drugs Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Future Directions of Marine Bacterial Natural Products

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 15394

Share This Special Issue

Special Issue Editor

Dr. Ronald O. Garcia

E-Mail Website
Guest Editor

Microbial Natural Product (MINS) Department, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS); German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany
Interests: microorganisms; myxobacteria; microbial natural products; drug discovery; phylogeny; taxonomy; systematics; metagenomics; genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine- and estuarine-derived bacteria are continuously gaining attention as a source of novel bioactive compounds. Marine actinobacteria, gliding bacteria, and myxobacteria are well-known producers of diverse secondary metabolites. Many of these natural compounds are novel and often associated with new bacterial strains. Metagenomic studies in salt-containing habitats and host organisms such as sponges, corals, and seagrasses indicate the presence of complex bacterial communities. Moreover, some studies have linked these possible bacterial associations with marine host organisms to the parallel production of similar compounds, as in the cases of apicularen A and salicylihalamide A, bengamide E and F, chondromide A–D and jasplakinolide, microsclerodermin D, and saframycin Mx1 and renieramycin A. Although the cultivation of these microorganisms may be very challenging due to the unknown or poorly understood physiology, marine bacteria may still be worth investigating to discover novel compounds.

It is a great pleasure to invite authors to submit their original research or review articles to this Special Issue within the wide scope of marine bacteria, their natural products, and the future direction for marine drug discovery.

Dr. Ronald O. Garcia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

marine- and estuarine-derived bacteria
gliding marine bacteria
marine myxobacteria
marine actinobacteria
bioactive compounds
marine metagenomics and biodiversity
marine natural products

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

15 pages, 2461 KiB

Open AccessArticle

New Deoxyenhygrolides from Plesiocystis pacifica Provide Insights into Butenolide Core Biosynthesis

by Joachim J. Hug, Louise Kjaerulff, Ronald Garcia and Rolf Müller

Mar. Drugs 2022, 20(1), 72; https://doi.org/10.3390/md20010072 - 14 Jan 2022

Cited by 8 | Viewed by 2036

Abstract

Marine myxobacteria present a virtually unexploited reservoir for the discovery of natural products with diverse biological functions and novel chemical scaffolds. We report here the isolation and structure elucidation of eight new deoxyenhygrolides (1–8) from the marine myxobacterium Plesiocystis pacifica DSM 14875^T. The herein described deoxyenhygrolides C–J (1–8) feature a butenolide core with an ethyl residue at C-3 of the γ-lactone in contrast to the previously described derivatives, deoxyenhygrolides A and B, which feature an isobutyl residue at this position. The butenolide core is 2,4-substituted with a benzyl (1, 2 and 7), benzoyl (3 and 4) or benzyl alcohol (5, 6 and 8) moiety in the 2-position and a benzylidene (1–6) or benzylic hemiketal (7 and 8) in the 4-position. The description of these new deoxyenhygrolide derivatives, alongside genomic in silico investigation regarding putative biosynthetic genes, provides some new puzzle pieces on how this natural product class might be formed by marine myxobacteria. Full article

(This article belongs to the Special Issue Future Directions of Marine Bacterial Natural Products)

► Show Figures

Figure 1

23 pages, 3415 KiB

Open AccessArticle

Insights into the Variation in Bioactivities of Closely Related Streptomyces Strains from Marine Sediments of the Visayan Sea against ESKAPE and Ovarian Cancer

by Edna M. Sabido, Chuckcris P. Tenebro, Dana Joanne Von L. Trono, Carmela Vannette B. Vicera, Sheeny Fane L. Leonida, Jose Jeffrey Wayne B. Maybay, Rikka Reyes-Salarda, Diana S. Amago, Angelica Marie V. Aguadera, May C. Octaviano, Jonel P. Saludes and Doralyn S. Dalisay

Mar. Drugs 2021, 19(8), 441; https://doi.org/10.3390/md19080441 - 31 Jul 2021

Cited by 11 | Viewed by 5626

Abstract

Marine sediments host diverse actinomycetes that serve as a source of new natural products to combat infectious diseases and cancer. Here, we report the biodiversity, bioactivities against ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) and ovarian cancer, and metabolites variation among culturable actinomycetes isolated from the marine sediments of Visayan Sea, Philippines. We identified 15 Streptomyces species based on a 16S rRNA gene sequence analysis. The crude extracts of 10 Streptomyces species have inhibited the growth of ESKAPE pathogens with minimum inhibitory concentration (MIC) values ranging from 0.312 mg/mL to 20 mg/mL depending on the strain and pathogens targeted. Additionally, ten crude extracts have antiproliferative activity against A2780 human ovarian carcinoma at 2 mg/mL. To highlight, we observed that four phylogenetically identical Streptomyces albogriseolus strains demonstrated variation in antibiotic and anticancer activities. These strains harbored type I and II polyketide synthase (PKS) and non-ribosomal synthetase (NRPS) genes in their genomes, implying that their bioactivity is independent of the polymerase chain reaction (PCR)-detected bio-synthetic gene clusters (BGCs) in this study. Metabolite profiling revealed that the taxonomically identical strains produced core and strain-specific metabolites. Thus, the chemical diversity among these strains influences the variation observed in their biological activities. This study expanded our knowledge on the potential of marine-derived Streptomyces residing from the unexplored regions of the Visayan Sea as a source of small molecules against ESKAPE pathogens and cancer. It also highlights that Streptomyces species strains produce unique strain-specific secondary metabolites; thus, offering new chemical space for natural product discovery. Full article

(This article belongs to the Special Issue Future Directions of Marine Bacterial Natural Products)

► Show Figures

Graphical abstract

Review

Jump to: Research

36 pages, 5608 KiB

Open AccessReview

Marine Bacterial Secondary Metabolites: A Treasure House for Structurally Unique and Effective Antimicrobial Compounds

by Ramanathan Srinivasan, Arunachalam Kannappan, Chunlei Shi and Xiangmin Lin

Mar. Drugs 2021, 19(10), 530; https://doi.org/10.3390/md19100530 - 23 Sep 2021

Cited by 41 | Viewed by 7091

Abstract

The prevalence of antimicrobial resistance reduces the effectiveness of antimicrobial drugs in preventing and treating infectious diseases caused by pathogenic organisms, such as bacteria, fungi, and viruses. Because of the burgeoning growth of microbes with antimicrobial-resistant traits, there is a dire need to identify and develop novel and effective antimicrobial agents to treat infections from antimicrobial-resistant strains. The marine environment is rich in ecological biodiversity and can be regarded as an untapped resource for prospecting novel bioactive compounds. Therefore, exploring the marine environment for antimicrobial agents plays a significant role in drug development and biomedical research. Several earlier scientific investigations have proven that bacterial diversity in the marine environment represents an emerging source of structurally unique and novel antimicrobial agents. There are several reports on marine bacterial secondary metabolites, and many are pharmacologically significant and have enormous promise for developing effective antimicrobial drugs to combat microbial infections in drug-resistant pathogens. In this review, we attempt to summarize published articles from the last twenty-five years (1996–2020) on antimicrobial secondary metabolites from marine bacteria evolved in marine environments, such as marine sediment, water, fauna, and flora. Full article

(This article belongs to the Special Issue Future Directions of Marine Bacterial Natural Products)

► Show Figures